Lilly will acquire Ajax Therapeutics in a deal worth up to $2.3B in upfront and contingent milestone payments to advance AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for MF/PV; subject to HSR clearance and customary closing conditions.
Key facts
AnnouncedApr 27, 2026
ClosedJun 10, 2026
Deal value$2.3B
Deal typeAcquisition/Merger
Therapeutic areaMyelofibrosis and polycythemia vera (myeloproliferative neoplasms)
IndicationsMyelofibrosis and polycythemia vera (myeloproliferative neoplasms)
Key assetsAJ1-11095 (Type II JAK2 inhibitor, small molecule, oral once-daily)
MechanismSelective Type II JAK2 inhibitor; binds JAK2 in inactive conformation for deeper, more durable pathway suppression than Type I inhibitors